tiprankstipranks
Trending News
More News >
SinoMab Bioscience Ltd. (HK:3681)
:3681
Hong Kong Market
Advertisement

SinoMab Bioscience Ltd.

Compare
1 Followers

3681 Stock Chart & Stats

HK$1.56
-HK$0.01(-1.00%)
At close: 4:00 PM EST
HK$1.56
-HK$0.01(-1.00%)

SinoMab Bioscience Ltd. News

3681 FAQ

What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$0.80 and its highest was HK$3.76 in the past 12 months.
    What is SinoMab Bioscience Ltd.’s market cap?
    SinoMab Bioscience Ltd.’s market cap is HK$2.19B.
      When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
      SinoMab Bioscience Ltd.’s upcoming earnings report date is Mar 23, 2026 which is in 141 days.
        How were SinoMab Bioscience Ltd.’s earnings last quarter?
        SinoMab Bioscience Ltd. released its earnings results on Aug 29, 2025. The company reported -HK$0.055 earnings per share for the quarter, missing the consensus estimate of -HK$0.053 by -HK$0.002.
          Is SinoMab Bioscience Ltd. overvalued?
          According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does SinoMab Bioscience Ltd. pay dividends?
            SinoMab Bioscience Ltd. does not currently pay dividends.
            What is SinoMab Bioscience Ltd.’s EPS estimate?
            SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does SinoMab Bioscience Ltd. have?
            SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
              What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
              SinoMab Bioscience Ltd. reported an EPS of -HK$0.055 in its last earnings report, missing expectations of -HK$0.053. Following the earnings report the stock price went up 2.597%.
                Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
                Currently, no hedge funds are holding shares in HK:3681

                SinoMab Bioscience Ltd. Stock Smart Score

                5
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Fundamentals

                Return on Equity
                -55.33%
                Trailing 12-Months
                Asset Growth
                -12.54%
                Trailing 12-Months

                Company Description

                SinoMab Bioscience Ltd.

                SinoMab Bioscience Ltd. (3681) is a biopharmaceutical company focused on the research, development, and commercialization of therapeutics for the treatment of immunological diseases. Based in Hong Kong, the company leverages its proprietary technology platforms to create innovative solutions targeting various autoimmune disorders. SinoMab's core products are monoclonal antibody drugs, which are designed to modulate the immune system and provide effective treatment options for patients suffering from conditions such as rheumatoid arthritis and other related diseases.

                SinoMab Bioscience Ltd. (3681) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                RemeGen Co. Ltd. Class H
                Shanghai Junshi Biosciences Co., Ltd. Class H
                Lepu Biopharma Co. Ltd. Class H
                Jiangsu Recbio Technology Co., Ltd. Class H
                Shanghai Henlius Biotech, Inc. Class H
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis